Abstract
The reported scale of repeat prescriptions ranges from 29% to 75% of all items prescribed, depending on the definition of repeat prescribing and other variables. It is likely that a substantial part of repeat prescribing by general practitioners (GPs) occurs without direct doctor-patient contact. While this reduces the workload for the GP and is convenient for the patient, it does not provide the adequate control that is needed to ensure that every repeat prescription is still appropriate, effective and well tolerated, and that it is still being viewed upon and taken by the patient as intended. Infrequent therapy reviews may lead to failure to prevent, identify and solve drug-related problems and drug wastage, and may, thereby, have a negative impact on the effectiveness, safety or cost of the medications prescribed.
Studies evaluating the repeat prescribing process have shown that GPs and medical practices vary widely in their degree of administrative and clinical control of repeat prescriptions. Contrary to the opinion that GPs cannot change prescribing behaviour when the prescription is initiated by a medical specialist, GPs have their own responsibility for controlling the repeats of such prescriptions.
Intervention studies suggest that a medication review by a pharmacist can help to reduce drug-related problems with repeat prescriptions, and the effectiveness of the intervention may be increased by combining the medication review with a consultation of the patient’s medical records and a patient interview. In several studies, such an intervention was relatively inexpensive and, therefore, feasible. However, these conclusions should be viewed with appropriate caution because a number of caveats pertain. There is still no evidence that these types of intervention improve health-related quality of life or reduce healthcare cost, and so far only a few trials have produced any evidence of clinical improvement. As implicit and explicit screening criteria have their own benefits and limitations, a combined application may offer a more thorough assessment but may also be more complex and time consuming.
Further studies on the development and evaluation of repeat prescription management models are needed, preferably focussing on improving clinical, humanistic and economic outcomes. New studies should investigate the effects of: different types of interventions; different organisational models; different target populations; and selecting and training different types of healthcare professionals. Future studies should also assess whether results are sustained, the optimal time interval between reviews of repeat prescriptions, and the possibilities offered by new computerised support technologies.
Similar content being viewed by others
References
Muir AJ, Sanders LL, Wilkinson WE, et al. Reducing medication regimen complexity: a controlled trial. J Gen Intern Med 2001; 16: 77–82
Khunti K, Kinsella B. Effect of systematic review of medication by general practitioner on drug consumption among nursinghome residents. Age Ageing 2000; 29: 451–3
Faulkner MA, Wadibia EC, Lucas BD, et al. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000; 20: 410–6
Rodgers S, Avery AJ, Meechan D, et al. Controlled trial of pharmacist intervention in general practice: the effect on prescribing costs. Br J Gen Pract 1999; 49: 717–20
Schrader SL, Dressing B, Blue R, et al. The Medication Reduction Project: combating polypharmacy in South Dakota elders through community-based interventions. S D J Med 1996; 49: 441–8
Carter BL, Malone DC, Valuck RJ, et al. The IMPROVE study: background and study design. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Am J Health Syst Pharm 1998; 55: 62–7
Wilson RG, Bojke C, O’Neill S, et al. Designing, specifying and evaluating a new repeat prescribing process for UK general practice. Stud Health Technol Inform 2000; 77: 219–23
National Audit Office. Repeat prescribing by general medical practitioners in England: HC 897. London: HM Stationary Office, 1993
Purves I, Kennedy J. The quality of general practice repeat prescribing. Newcastle upon Tyne, UK: The Sowerby Unit for Primary Care Informatics, University of Newcastle, 1994 [online]. Available from URL: http://www.schin.ncl.ac.uk/RepeatPrescribing/material/reports/repeat%20prescribing%201%20report.pdf [Accessed 2003 Jul 6]
Sykes D, Westwood P, Gilleghan J. Development of a review programme for repeat prescription medicines. Pharm J 1996; 256: 458–60
Zermansky AG. Who controls repeats? Br J Gen Pract 1996; 46: 643–7
Harris CM, Dajda R. The scale of repeat prescribing. Br J Gen Pract 1996; 46: 649–53
Granås AG, Bates I. The effect of pharmaceutical review of repeat prescriptions in general practice. Int J Pharm Pract 1999; 7: 264–75
Rokstad K, Straand J. Drug prescribing during direct and indirect contacts with patients in general practice: a report from the More & Romsdal Prescription Study. Scand J Prim Health Care 1997; 15: 103–8
Davidson W, Collett J, Jackson C, et al. Identification and costs of prescriber-defined repeat prescribing. Int J Pharm Pract 1997; 5: 46–9
Feely J, Chan R, McManus J, et al. The influence of hospital-based prescribers on prescribing in general practice. Pharmacoeconomics 1999; 16: 175–81
Straand J, Rokstad KS. Elderly patients in general practice: diagnoses, drugs and inappropriate prescriptions: a report from the More & Romsdal Prescription Study. Fam Pract 1999; 16: 380–8
Bond C, Matheson C, Williams S, et al. Repeat prescribing: a role for community pharmacists in controlling and monitoring repeat prescriptions. Br J Gen Pract 2000; 50: 271–5
Goldstein R, Hulme H, Willits J. Reviewing repeat prescribing: general practitioners and community pharmacists working together. Int J Pharm Pract 1998; 6: 60–6
McGavock H, Wilson-Davis K, Connolly JP. Repeat prescribing management: a cause for concern? Br J Gen Pract 1999; 49: 343–7
Quinn R, Kelly A. How much of a general practitioner’s prescribing is outside his/her control? Ir Med J 1998; 91: 168–72
Corry M, Bonner G, McEntee S, et al. Hospitals do not inform GPs about medication that should be monitored. Fam Pract 2000; 17: 268–71
de Vries CS, van Diepen NM, Tromp TF, et al. Auditing GPs’ prescribing habits: cardiovascular prescribing frequently continues medication initiated by specialists. Eur J Clin Pharmacol 1996; 50: 349–52
Borgsdorf LR, Miano JS, Knapp KK. Pharmacist-managed medication review in a managed care system. Am J Hosp Pharm 1994; 51: 772–7
Jameson J, VanNoord G, Vanderwoud K. The impact of a pharmacotherapy consultation on the cost and outcome of medical therapy. J Fam Pract 1995; 41: 469–72
Cassidy IB, Keith MR, Coffey EL, et al. Impact of pharmacist-operated general medicine chronic care refill clinics on practitioner time and quality of care. Ann Pharmacother 1996; 30: 745–51
Hanlon JT, Weinberger M, Samsa GP, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med 1996; 100: 428–37
Hanlon JT, Landsman PB, Cowan K, et al. Physician agreement with pharmacist-suggested drug therapy changes for elderly outpatients. Am J Health Syst Pharm 1996; 53: 2735–7
Cowper PA, Weinberger M, Hanlon JT, et al. The cost-effectiveness of a clinical pharmacist intervention among elderly outpatients. Pharmacotherapy 1998; 18: 327–32
Burtonwood AM, Hinchliffe AL, Tinkler GS. A prescription for quality: a role for the clinical pharmacist in general practice. Pharm J 1998; 261: 678–80
Grymonpre RE, Williamson DA, Montgomery PR. Impact of a pharmaceutical care model for non-institutionalised elderly: results of a randomised, controlled trial. Int J Pharm Pract 2001; 9: 235–41
Jones J, Matheson C, Bond C. Patient satisfaction with a community pharmacist-managed system of repeat prescribing. Int J Pharm Pract 2000; 8: 291–7
Mackie CA, Lawson DH, Campbell A, et al. A randomised controlled trial of medication review in patients receiving polypharmacy in general practice [abstract]. Pharm J 1999; 263 Suppl.: R7
Monane M, Matthias DM, Nagle BA, et al. Improving prescribing patterns for the elderly through an online drug utilization review intervention: a system linking the physician, pharmacist, and computer. JAMA 1998; 280: 1249–52
Krass I, Smith C. Impact of medication regimen reviews performed by community pharmacists for ambulatory patients through liaison with general medical practitioners. Int J Pharm Pract 2000; 8: 111–20
Jameson JP, VanNoord GR. Pharmacotherapy consultation on polypharmacy patients in ambulatory care. Ann Pharmacother 2001; 35: 835–40
Lowe CJ, Raynor DK, Purvis J, et al. Effects of a medicine review and education programme for older people in general practice. Br J Clin Pharmacol 2000; 50: 172–5
Ellis SL, Billups SJ, Malone DC, et al. Types of interventions made by clinical pharmacists in the IMPROVE study: Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000; 20: 429–35
Malone DC, Carter BL, Billups SJ, et al. An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000; 20: 1149–58
Malone DC, Carter BL, Billups SJ, et al. Can clinical pharmacists affect SF-36 scores in veterans at high risk for medication-related problems? Med Care 2001; 39: 113–22
Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000; 20: 1508–16
Sellors C, Dalby DM, Howard M, et al. Community-based family practices: a randomized, controlled trial in seniors. J Pharm Technol 2001; 17: 264–9
Allard J, Hebert R, Rioux M, et al. Efficacy of a clinical medication review on the number of potentially inappropriate prescriptions prescribed for community-dwelling elderly people. CMAJ 2001; 164: 1291–6
Krska J, Cromarty JA, Arris F, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing 2001; 30: 205–11
Zermansky AG, Petty DR, Raynor DK, et al. Randomised controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice. BMJ 2001; 323: 1340–3
Zermansky AG, Petty DR, Raynor DK, et al. Clinical medication review by a pharmacist of patients on repeat prescriptions in general practice: a randomised controlled trial. Health Technol Assess 2002; 6(20): 1–86
Petty DR, Zermansky AG, Raynor DK, et al. Clinical medication review by a pharmacist of elderly patients on repeat medications in general practice: pharmacist interventions and review outcomes. Int J Pharm Pract 2002; 10: 39–46
Petty DR, Knapp P, Raynor DK, et al. Clinical medication review in general practice: what is the benefit of a second review [abstract]. Int J Pharm Pract 2002; 10 Suppl.: R70
Krska J, Ross S. Medication review: whose job it is? [abstract]. Int J Pharm Pract 2002; 10 Suppl.: R86
Sellors J, Kaczorowski J, Sellors C, et al. A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. CMAJ 2003; 169: 17–22
Starfield B, Powe NR, Weiner JR, et al. Costs vs quality in different types of primary care settings. JAMA 1994; 272: 1903–8
Warholak-Juarez T, Rupp MT, Salazar TA, et al. Effect of patient information on the quality of pharmacists’ drug use review decisions. J Am Pharm Assoc (Wash) 2000; 40: 500–8
Anderson GM, Lexchin J. Strategies for improving prescribing practice. CMAJ 1996; 154: 1013–7
Grimshaw JM, Shirran L, Thomas R, et al. Changing provider behavior: an overview of systematic reviews of interventions. Med Care 2001; 39 Suppl. 2: II2–II45
Mason JD, Colley CA. Effectiveness of an ambulatory care clinical pharmacist: a controlled trial. Ann Pharmacother 1993; 27: 555–9
Majumdar SR, Soumerai SB. Why most interventions to improve physician prescribing do not seem to work. CMAJ 2003; 169: 30–1
Britton ML, Lurvey PL. Impact of medication profile review on prescribing in a general medicine clinic. Am J Hosp Pharm 1991; 48: 265–70
Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533–43
Schmader KE, Hanlon JT, Landsman PB, et al. Inappropriate prescribing and health outcomes in elderly veteran outpatients. Ann Pharmacother 1997; 31: 529–33
Shelton PS, Fritsch MA, Scott MA. Assessing medication appropriateness in the elderly: a review of available measures. Drugs Aging 2000; 16: 437–50
Zuckerman IH, Mulhearn DM, Metge CJ. Inter- and intrarater reliability of retrospective drug utilization reviewers. J Am Pharm Assoc (Wash) 1999; 39: 45–9
Soumerai SB, Lipton HL. Computer-based drug-utilization review: risk, benefit, or boondoggle? N Engl J Med 1995; 332: 1641–5
Hennessy S, Bilker WB, Zhou L, et al. Retrospective drug utilization review, prescribing errors, and clinical outcomes. JAMA 2003; 290: 1494–9
Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157: 1531–6
Aparasu RR, Mort JR. Inappropriate prescribing for the elderly: Beers criteria-based review. Ann Pharmacother 2000; 34: 338–46
Graal MB, Wolffenbuttel BH. The use of sulphonylureas in the elderly. Drugs Aging 1999; 15: 471–81
Stahl M, Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 1999; 16: 586–90
Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667–71
Rogers JF, Nafziger AN, Bertino Jr JS. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002; 113: 746–50
Maitland-Van Der Zee AH, Klungel OH, Stricker BH, et al. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002; 163: 213–22
Cohen JS. Avoiding adverse reactions: effective lower-dose drug therapies for older patients. Geriatrics 2000; 55: 54–60,63
Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000; 16: 165–77
Gosselink AT, van Veldhuisen DJ, Crijns HJ. When, and when not, to use digoxin in the elderly. Drugs Aging 1997; 10: 411–20
Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA 2001; 286: 2839–44
Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173–92
Macfarlane J, Prewett J, Rose D, et al. Prospective case-control study of role of infection in patients who reconsult after initial antibiotic treatment for lower respiratory tract infection in primary care. BMJ 1997; 315: 1206–10
Saunders K, Simon G, Bush T, et al. Assessing the feasibility of using computerized pharmacy refill data to monitor antidepressant treatment on a population basis: a comparison of automated and self-report data. J Clin Epidemiol 1998; 51: 883–90
Hirschfeld RM. Antidepressants in long-term therapy: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 35–8
Gray J, Majeed A, Kerry S, et al. Identifying patients with ischaemic heart disease in general practice: cross sectional study of paper and computerised medical records. BMJ 2000; 321: 548–50
Weideman RA, Bernstein IH, McKinney WP. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm 1999; 56: 1524–9
Halkin H, Katzir I, Kurman I, et al. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 2001; 69: 260–5
Stewart RB, Cooper JW. Polypharmacy in the aged: practical solutions. Drugs Aging 1994; 4: 449–61
Hamdy RC, Moore SW, Whalen K, et al. Reducing polypharmacy in extended care. South Med J 1995; 88: 534–8
Williams BR, Nichol MB, Lowe B, et al. Medication use in residential care facilities for the elderly. Ann Pharmacother 1999; 33: 149–55
Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888–99
Fastbom J, Claesson CB, Cornelius C, et al. The use of medicines with anticholinergic effects in older people: a population study in an urban area of Sweden. J Am Geriatr Soc 1995; 43: 1135–40
Campbell SM, Roland MO, Shekelle PG, et al. Development of review criteria for assessing the quality of management of stable angina, adult asthma, and non-insulin dependent diabetes mellitus in general practice. Qual Health Care 1999; 8: 6–15
Bouvy ML, Heerdink ER, Klungel OH, et al. Women with angina pectoris receive less antiplatelet treatment than men. Br J Gen Pract 1999; 49: 299–300
Romeijnders AC, Elders PJ. Summary of the guideline ‘Osteoporosis’ of the Dutch College of General Practitioners: Dutch College of General Practitioners [in Dutch]. Ned Tijdschr Geneeskd 1999; 143: 1611–4
Diette GB, Wu AW, Skinner EA, et al. Treatment patterns among adult patients with asthma: factors associated with overuse of inhaled beta-agonists and underuse of inhaled corticosteroids. Arch Intern Med 1999; 159: 2697–704
Walters EH, Walters J. Inhaled short acting beta2-agonist use in asthma: regular vs as needed treatment (Cochrane Review). Cochrane Database Syst Rev 2000; (4): CD001285
Anis AH, Lynd LD, Wang XH, et al. Double trouble: impact of inappropriate use of asthma medication on the use of health care resources. CMAJ 2001; 164: 625–31
Diener HC, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs 1998; 56(5): 811–24
Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50: 105–16
Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37: 846–57
Jones JK, Gorkin L, Lian JF, et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995; 311: 293–5
Ambrosioni E, Leonetti G, Pessina AC, et al. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 2000; 18: 1691–9
Murphy JE. Generic substitution and optimal patient care. Arch Intern Med 1999; 159: 429–33
Suh DC. Trends of generic substitution in community pharmacies. Pharm World sci 1999; 21: 260–5
McAlister FA, Laupacis A, Wells GA, et al. Users’ guides to the medical literature. XIX: applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999; 282: 1371–7
Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? Lancet 1999; 354: 1202–4
Acknowledgements
Peter De Smet works for the Scientific Institute Dutch Pharmacists, which is financially dependent on the Royal Dutch Society for the Advancement of Pharmacy (the professional pharmaceutical association in The Netherlands). The authors have no further sources of funding or conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
De Smet, P.A.G.M., Dautzenberg, M. Repeat Prescribing. Drugs 64, 1779–1800 (2004). https://doi.org/10.2165/00003495-200464160-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200464160-00005